BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (NASDAQ:SGEN - News) today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. A summary of the companys poster presentations is below and full abstracts can be accessed on the ASCO website at http://www.abstract.asco.org.

ADCETRIS

Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study

CD30 expression in non-lymphomatous malignancies

Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study

ASG-5ME

Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC)

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

See the rest here:

Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting